Pfizer Inc. (PFE)
Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact
On Monday, Sangamo Therapeutics, Inc. SGMO regained the development and commercialization rights to giroctocogene fitelparvovec, an investigational gene therapy product candidate for moderately severe to severe hemophilia A that it has co-developed with and licensed to Pfizer Inc PFE.
3 Reasons to Buy Pfizer Stock Like There's No Tomorrow
The pharmaceutical industry can be a tough business. Companies must innovate constantly to stay relevant because patents protecting their proprietary drugs expire.
Pfizer: 4 Reasons to Buy This Stock
Pharmaceutical giant Pfizer Inc. NYSE: PFE stock is trading back down near its pandemic lows. Every time it attempts to climb over the $30 mark, something causes shares to slide right back down.
Sangamo Therapeutics down 50% premarket on Pfizer blow
Shares in Sangamo Therapeutics dropped 50% premarket after Pfizer Inc (NYSE:PFE, ETR:PFE) ended its collaboration on a gene therapy for haemophilia The drug, giroctocogene fitelparvovec, met its target in a late-stage trial, with Pfizer previously expected to seek regulatory approval in 2025. “We were extremely surprised and very disappointed,” said Sangamo's CEO, Sandy Macrae.
Sangamo to reclaim hemophilia A therapy rights post Pfizer termination
Sangamo Therapeutics said on Monday it would regain full rights to its hemophilia A gene therapy after co-development partner Pfizer terminated the agreement.
25 Worst Stocks to Own in January
As President-elect Donald Trump prepares for his inauguration, his administration is gearing up to roll out significant policy shifts.
Pfizer: One Of The Next Big AI Winners
Kirk Spano thinks Pfizer is poised to be a major AI winner, especially in cancer treatment. Potentially making it easier to manage like AIDS.
Prediction: This $43 Billion Bet Will Help Pfizer Stock Take Off in 2025.
Pfizer (PFE 0.23%) became a stock market star in early pandemic days as it brought the first coronavirus vaccine to market. The company generated billions of dollars in revenue thanks to its coronavirus vaccine and treatment, even reaching a record of more than $100 billion in total company revenue in 2022.
Pfizer (PFE) Suffers a Larger Drop Than the General Market: Key Insights
Pfizer (PFE) closed the most recent trading day at $26.56, moving -0.67% from the previous trading session.
Better Income Stock: Pfizer or Altria Group?
High-yield dividend stocks often catch investors' attention -- and for good reason. When established companies maintain larger-than-average dividend payments, they can provide both substantial current income and the potential for long-term appreciation.
Pfizer's Progress on C. diff Vaccine and Pneumococcal Shot Wins Analyst Conviction
Pfizer hosted a discussion with sell-side analysts to provide an update on one of the vaccine pipeline items – a second-generation Clostridioides difficile (C. diff) vaccine effort in Phase 2.
Should Value Investors Buy Pfizer (PFE) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
